Loading stock data…
VNDA
$7.00-0.10 (-1.41%)
Market ClosedLast close May 1
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vanda Pharmaceuticals Inc. in the Healthcare sector is trading at $7.00. The stock is currently 30% below its 52-week high of $9.94, remaining 14.8% above its 200-day moving average. Technical signals show neutral RSI of 46 and bullish MACD crossover, explaining why VNDA maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.00
Potential Upside
5%
Whystock Fair Value$7.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$395.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.46%
Volume
Today's trading volume
787,585
Recent News
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +31.29% and +4.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer
Geron Corporation (NASDAQ:GERN) is one of the best growth stocks under $10 to invest in. On April 13, Geron Corporation appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. A seasoned legal executive, Williams joins the commercial-stage biopharma firm from Vanda Pharmaceuticals, where he served as Senior Vice President and General […]
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index adding 0.1% a
Sector Update: Health Care Stocks Advance in Afternoon Trading
Health care stocks advanced Thursday afternoon, with the NYSE Health Care Index adding 0.3% and the
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares
AnaptysBio's (ANAB) board has approved the planned spin-off of First Tracks Biotherapeutics and a re